HSBC starts majority of pharma stocks with Buy - Bayer, however ... - Marketscreener.com
| LZAGY Stock | USD 58.93 0.13 0.22% |
Slightly above 55% of Lonza Group's investor base is interested to short. The analysis of overall sentiment of trading Lonza Group AG pink sheet suggests that many investors are impartial at this time. Lonza Group's investing sentiment can be driven by a variety of factors including economic data, Lonza Group's earnings reports, geopolitical events, and overall market trends.
Lonza |
HSBC starts majority of pharma stocks with Buy - Bayer, however ... Marketscreener.com
Read at news.google.com
 |
Lonza Group Fundamental Analysis
We analyze Lonza Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lonza Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lonza Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Lonza Group is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Lonza Group AG Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lonza Group pink sheet to make a market-neutral strategy. Peer analysis of Lonza Group could also be used in its relative valuation, which is a method of valuing Lonza Group by comparing valuation metrics with similar companies.
Peers
Lonza Group Related Equities
| APDN | Applied DNA | 17.65 | ||||
| MYGN | Myriad Genetics | 3.09 | ||||
| SKHCF | Sonic Healthcare | 0.70 | ||||
| NEOG | Neogen | 0.46 | ||||
| TWST | Twist Bioscience | 0.17 | ||||
| TMO | Thermo Fisher | 0.26 | ||||
| WAT | Waters | 0.42 | ||||
| DHR | Danaher | 0.67 | ||||
| SHC | Sotera Health | 0.75 | ||||
| MTD | Mettler Toledo | 0.86 | ||||
| ICLR | ICON PLC | 1.49 | ||||
| IQV | IQVIA Holdings | 1.57 | ||||
| RVTY | Revvity | 2.04 | ||||
| RDNT | RadNet | 3.30 | ||||
| PSNL | Personalis | 5.49 | ||||
| PRPH | ProPhase Labs | 6.94 |
Additional Tools for Lonza Pink Sheet Analysis
When running Lonza Group's price analysis, check to measure Lonza Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lonza Group is operating at the current time. Most of Lonza Group's value examination focuses on studying past and present price action to predict the probability of Lonza Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lonza Group's price. Additionally, you may evaluate how the addition of Lonza Group to your portfolios can decrease your overall portfolio volatility.